抗腫瘍療法のための腫瘍ストロマルマイクロ環境における翻訳後の修正を標的とする
Huiguo Qing1,2,3, Xiangyan Jiang1,2,3, Yong Ma1,2,3
1Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, China.
Molecular carcinogenesis
|August 20, 2025
まとめ
PTMは腫瘍の微小環境を調節し,がんの進行と治療耐性を影響する. 腫瘍のストロマにPTMを 標的として置くことは 癌治療の新たな方向性を示します
科学分野:
- 腫瘍学
- 分子生物学
- 生物化学
背景:
- 腫瘍のストロマ環境は,ストロマ細胞と細胞外マトリックス (ECM) を含み,腫瘍の悪性および治療に対する耐性を有意に影響する.
- 信号伝達経路,代謝調節,細胞サイクルダイナミクスは,腫瘍の微小環境に影響する重要な要因です.
- 翻訳後の改変 (PTM) は,がんにおける確立された役割を持つタンパク質機能の重要な調節因子である.
研究 の 目的:
- 腫瘍ストロマの微小環境における PTM の調節的役割を探求する.
- PTMを標的としたがん治療における最近の進歩をレビューする.
- 腫瘍学における新しい治療戦略としてPTMを強調する.
主な方法:
- PTMと腫瘍マイクロ環境に関する研究の文献レビュー.
- ストロマ細胞の行動,信号伝達,ECM再構成に対するPTMの影響の分析.
- PTMを中心とした現在および新興がん治療の検討.
主要な成果:
- PTMは,細胞の行動とECM組成を含む腫瘍ストロマの微環境の様々な側面を調節する.
- PTMは腫瘍の発症,進行,転移,および治療抵抗性の発生に関与しています.
- PTMをターゲットにすることで,腫瘍の成長と生存に不可欠なストロマ成分に影響を与えます.
結論:
- PTMは腫瘍ストロマの微小環境において重要な調節的役割を果たします.
- 腫瘍ストロマにおけるPTMの調節は新しいがん治療法にとって有望な道を示しています
- PTMをターゲットにすることで 癌治療の成果を向上させる新たな戦略的方向性を 提供できます
さらに関連する動画
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
672
07:44Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
7.6K
関連する概念動画
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
